Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.
暂无分享,去创建一个
F. Raffi | O. Launay | G. Pialoux | J. Devaster | J. Delfraissy | F. Roman | C. Durier | C. Desaint | P. Loulergue | X. Duval | J. Reynes | D. Rey | C. Jacomet | J. Ghosn | F. Ajana | J. Aboulker | N. Colin de Verdière | V. Foubert
[1] Anthony S. Fauci,et al. Influenza vaccines for the future. , 2010, The New England journal of medicine.
[2] I. Frank,et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals , 2010, AIDS.
[3] M. Bickel,et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients , 2010, AIDS (London).
[4] J. Devaster,et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. , 2010, Vaccine.
[5] K. Hoschler,et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.
[6] X. Zhang,et al. A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.
[7] C. Wichems,et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.
[8] Felipe García,et al. Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. , 2009, AIDS research and human retroviruses.
[9] E. Janoff,et al. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. , 2009, The Lancet. Infectious diseases.
[10] H. Furrer,et al. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] L. Sticchi,et al. Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults , 2007, Clinical and Vaccine Immunology.
[12] R. G. Das,et al. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. , 2007, Vaccine.
[13] S. Oka,et al. Efficacy and Immunologic Responses to Influenza Vaccine in HIV-1-Infected Patients , 2005, Journal of acquired immune deficiency syndromes.
[14] K. Neuzil,et al. Cardiopulmonary Hospitalizations During Influenza Season in Adults and Adolescents With Advanced HIV Infection , 2003, Journal of acquired immune deficiency syndromes.
[15] R. Bugarini,et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. , 2003, Vaccine.
[16] D. Skiest,et al. Comparison of the effects of acute influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[17] C. V. Hoecke,et al. Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix™ , 2002 .
[18] K. Nichol,et al. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. , 2001, Archives of internal medicine.
[19] K. Neuzil,et al. Influenza-associated morbidity and mortality in young and middle-aged women. , 1999, JAMA.
[20] Programmierbarer Thermoblock,et al. From industry , 1991 .